In the field of bone repair, the inorganic–organic composite scaffold is a promising strategy for mimicking the compositions of the natural bone. In addition, as implants for repairing load-bearing sites, an inert permanent bone substitute composites with bioactive degradable ingredients may make full use of the composite scaffold. Herein, the porous zirconia (ZrO₂) matrix was prepared via the template replication method, and the partial degradable ZrO₂–chitosan particles–GelMA composite scaffolds with different chitosan/GelMA volume ratios were prepared through the vacuum infiltration method. Dynamic light scattering (DLS) and the scanning electron microscope (SEM) were adopted to observe the size of the chitosan particles and the morphologies of the composites scaffold. The mechanical properties, swelling properties, and degradation properties of the composite scaffolds were also characterized by the mechanical properties testing machine and immersion tests. The CCK-8 assay was adopted to test the biocompatibility of the composite scaffold preliminarily. The results show that chitosan particles as small as 60 nm were obtained. In addition, the ratio of chitosan/GelMA can influence the mechanical properties and the swelling and degradation behaviors of the composites scaffold. Furthermore, improved cell proliferation performance was obtained for the composite scaffolds.

Antibody–drug conjugates (ADCs) represent a transformative class of targeted therapies designed to deliver potent cytotoxic agents specifically to tumor cells, minimizing systemic toxicity. This review provides a comprehensive overview of ADCs, detailing their mechanisms of action, design strategies, and clinical advancements. ADCs utilize monoclonal antibodies to selectively bind tumor-associated antigens, enabling the precise delivery of toxic payloads to cancer cells. The review explores the critical components of ADCs, including the antibody, linker, and payload, and highlights how these elements can be optimized to improve efficacy and minimize off-target effects. We examine the evolution of ADC design from early constructs to the latest innovations and the development of novel payloads that extend therapeutic possibilities beyond traditional cytotoxic agents. Additionally, we discuss the clinical success of ADCs, with examples from approved therapies such as gemtuzumab ozogamicin, brentuximab vedotin, and trastuzumab emtansine, which have redefined the treatment landscape for various cancers. Despite their success, ADCs face challenges such as tumor heterogeneity, resistance mechanisms, and toxicity, which are actively being addressed through ongoing research. The review concludes with an outlook on the future of ADCs, highlighting emerging strategies in conjugation technology, payload design, and combination therapies that are poised to enhance their therapeutic potential across oncology and other disease areas.

Insufficient bone mass is still a difficult point to be solved in oral implantation, so new bone graft materials are continuously researched and discussed in clinical practice in order to obtain better bone augmentation. In order to explore whether platelet-rich fibrin (PRF) can promote the formation of new bone in mineralized collagen (MC), MC/PRF and pure MC were implanted into the bilateral mandibular defect model in rabbits, respectively. Micro-CT scan and histological evaluation of the target area at 4, 8, and 12 weeks after operation. The results of Micro-CT three-dimensional reconstruction analysis showed that the ratio of bone volume to total volume (BV/TV), trabecular bone number (Tb.N), trabecular bone thickness (Tb.Th) and trabecular bone separation (Tb.Sp) and residual material volume fraction (RMVF) in the MC/PRF group were better than those in the MC group (p<0.05). The results of HE and Masson staining showed that the new bone formation and material degradation rate of the MC/PRF group were better than those of the MC group. The results suggest that PRF can accelerate the formation of new bone in MC, and provide new ideas for the clinical application of new bone graft materials.

Increasing attention has been directed to the study of the automatic emotion recognition in human speech recently. This paper presents an approach for recognizing negative emotions in spoken dialogs at the utterance level. Our approach mainly includes two parts. First, in addition to the traditional acoustic features, linguistic features based on distributed representation are extracted from the text transcribed by an automatic speech recognition (ASR) system. Second, we propose a novel deep learning model, multi-feature stacked denoising autoencoders (MSDA), which can fuse the high-level representations of the acoustic and linguistic features along with contexts to classify emotions. Experimental results demonstrate that our proposed method yields an absolute improvement over the traditional method by 5.2 %.

Cancer evolves within tissue ecosystems in which innate immune surveillance and tumor-promoting inflammation jointly shape disease progression and therapeutic response. Innate receptors detect cellular stress, altered-self ligands, damaged-cell products and tumor-derived nucleic acids, thereby initiating cytotoxicity, phagocytosis, antigen presentation and adaptive immune priming. However, tumors can redirect these mechanisms through suppressive cytokines, metabolic competition, hypoxia and dysregulated chemokine networks, promoting immune exclusion, metastasis and treatment resistance. This Review examines innate recognition, immunoediting and innate–adaptive crosstalk. We discuss the heterogeneity, dysfunction and therapeutic targeting of dendritic cells, macrophages, natural killer cells, neutrophils, myeloid-derived suppressor cells, innate lymphoid cells and other tissue-resident populations. We also evaluate Toll-like receptor, cGAS–STING, RIG-I–MAVS, inflammasome and complement pathways as therapeutically actionable but potentially tumor-promoting signaling systems. Finally, we consider how innate adjuvants, antigen selection, delivery technologies and rational combinations can improve therapeutic cancer vaccines. Emerging clinical studies demonstrate feasibility, but inconsistent efficacy and treatment-associated toxicity emphasize the need for biomarker-guided patient selection, spatially restricted delivery and mechanism-based sequencing. Clinical translation will depend on biomarker-guided patient selection, localized delivery and treatment sequencing that preserves antimicrobial defense and tissue homeostasis.